SeaStar Medical announces 2026 milestones

SeaStar Medical (ICU) announced today its key milestones for 2026. Key 2026 milestones for SeaStar Medical include the following: Broaden QUELIMMUNE adoption to include 15 additional top-ranked children’s medical centers, more than doubling the total number of sites and building increased depth in customer orders. SeaStar Medical anticipates achieving approximately $2 million in net product revenue in 2026. Advance the SCD therapy for the adult AKI indication through completion of enrollment in the NEUTRALIZE-AKI pivotal trial near the end of 2026 and initiation of a modular PMA process. Evaluate broader applicability of the SCD therapy through the conduct of a pivotal trial of the SCD therapy in patients with acute CHF with cardiorenal syndrome awaiting LVAD implantation. Explore rapid regulatory pathways to commercialization of the SCD therapy as a first-in-class therapy, designed to save lives and spare organ function in numerous destructive hyperinflammatory conditions. SeaStar Medical will seek additional Humanitarian Use and Breakthrough Device Designations to potentially provide lifesaving support to these patients.